In patients with recurrent or metastatic cervical cancer, treatment with the antibody–drug conjugate tisotumab vedotin-tftv (Tivdak, Seagen/Genmab) reduced the risk for death by 30% compared with investigator’s choice chemotherapy, according to results of the phase 3 innovaTV 301 trial.
In the global study, which was presented at the 2023 annual congress of the European Society for Medical Oncology (ESMO; abstract LBA9), 502 patients, with a median age of 50 years, were randomized to
NOVEMBER 6, 2023